AnaptysBio (NASDAQ:ANAB) Trading 6.9% Higher – Should You Buy?

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price shot up 6.9% on Tuesday . The stock traded as high as $36.54 and last traded at $37.1740. 102,333 shares changed hands during trading, a decline of 86% from the average session volume of 710,718 shares. The stock had previously closed at $34.77.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ANAB shares. Wedbush reaffirmed an “outperform” rating and set a $50.00 price target on shares of AnaptysBio in a research report on Monday, November 10th. Wells Fargo & Company upped their target price on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Barclays lowered their target price on AnaptysBio from $83.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.40.

AnaptysBio Price Performance

The business has a fifty day moving average of $30.29 and a 200 day moving average of $25.26. The stock has a market cap of $1.03 billion, a PE ratio of -13.14 and a beta of 0.16.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ANAB. Larson Financial Group LLC increased its position in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the last quarter. Rhumbline Advisers raised its stake in AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after buying an additional 826 shares in the last quarter. US Bancorp DE lifted its holdings in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after buying an additional 979 shares during the last quarter. Bessemer Group Inc. grew its position in shares of AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Corton Capital Inc. increased its holdings in shares of AnaptysBio by 12.2% in the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 1,305 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.